PELLEGATA, NATALIA SIMONA
 Distribuzione geografica
Continente #
NA - Nord America 1.782
AS - Asia 1.245
EU - Europa 961
SA - Sud America 185
AF - Africa 105
Continente sconosciuto - Info sul continente non disponibili 74
OC - Oceania 3
Totale 4.355
Nazione #
US - Stati Uniti d'America 1.727
CN - Cina 446
SG - Singapore 299
HK - Hong Kong 207
IE - Irlanda 201
IT - Italia 144
BR - Brasile 141
RU - Federazione Russa 137
VN - Vietnam 113
DE - Germania 108
FR - Francia 91
FI - Finlandia 79
ZA - Sudafrica 78
UA - Ucraina 66
GB - Regno Unito 37
BD - Bangladesh 33
SE - Svezia 31
IN - India 30
CA - Canada 26
MX - Messico 17
JP - Giappone 15
IQ - Iraq 14
TR - Turchia 14
ES - Italia 13
AR - Argentina 12
AT - Austria 11
PK - Pakistan 10
PL - Polonia 10
CO - Colombia 9
ID - Indonesia 9
SA - Arabia Saudita 9
BE - Belgio 8
NL - Olanda 7
EG - Egitto 6
KE - Kenya 6
LT - Lituania 6
PH - Filippine 6
CL - Cile 5
EC - Ecuador 5
JO - Giordania 5
MA - Marocco 5
TH - Thailandia 4
UZ - Uzbekistan 4
KG - Kirghizistan 3
KH - Cambogia 3
MY - Malesia 3
PE - Perù 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
ET - Etiopia 2
IL - Israele 2
IS - Islanda 2
JM - Giamaica 2
KR - Corea 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
PY - Paraguay 2
VE - Venezuela 2
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
CD - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
IR - Iran 1
LB - Libano 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PF - Polinesia Francese 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
ZM - Zambia 1
Totale 4.282
Città #
San Jose 209
Hong Kong 202
Dublin 198
Chandler 186
Ashburn 184
Singapore 146
Dallas 138
Beijing 123
Council Bluffs 86
Boardman 75
Johannesburg 71
Jacksonville 61
Lauterbourg 57
Nanjing 57
Los Angeles 53
Helsinki 46
Ho Chi Minh City 39
Moscow 33
Redondo Beach 33
Lawrence 32
Princeton 32
Medford 30
Munich 28
Wilmington 28
Falkenstein 26
Santa Clara 26
Hanoi 24
Milan 24
New York 21
Hebei 19
Jiaxing 18
Buffalo 17
Columbus 17
Nanchang 17
Shanghai 17
Chicago 16
São Paulo 16
The Dalles 15
Shenyang 14
Tokyo 14
Changsha 13
Monza 13
Chennai 12
Da Nang 12
Orem 12
Seattle 12
Brooklyn 11
Florence 11
Pavia 11
Tianjin 11
Toronto 11
Montreal 10
Ann Arbor 9
Denver 9
Germering 9
Phoenix 9
Atlanta 8
Brussels 8
Istanbul 8
Boston 7
Frankfurt am Main 7
Rio de Janeiro 7
Secaucus 7
Warsaw 7
Guangzhou 6
Rome 6
Verona 6
Amman 5
Biên Hòa 5
Bologna 5
Cape Town 5
Haiphong 5
Kolkata 5
Nairobi 5
Padova 5
San Francisco 5
Vienna 5
Carbonara Scrivia 4
Caserta 4
Curitiba 4
Córdoba 4
Dhaka 4
Falls Church 4
Genoa 4
Hangzhou 4
Houston 4
Mosul 4
Newark 4
Tashkent 4
Alessandria 3
Amsterdam 3
Baghdad 3
Bishkek 3
Brasília 3
Cairo 3
Chiang Mai 3
Jakarta 3
Jaú 3
Manassas 3
Medellín 3
Totale 2.831
Nome #
Analysis and clinical implications of K-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix 160
Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions 133
K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma 128
Primary retroperitoneal mucinous cystoadenocarcinomas: an immunohistochemical and molecular study 117
K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions 115
Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. 109
The novel SSTR3 full agonist ITF2984 shows antitumor properties against pancreatic neuroendocrine tumors (Pan-NETs) 107
A 5'-truncated c-myc gene variant not associated with a risk of cancer 103
Genetic events in sporadic colorectal adenomas; K-ras and p53 heterozygous mutations are not sufficient for malignant progression 97
Loss of heterozygosity and K-ras gene mutations in gastric cancer 96
Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients 96
Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects 92
Base transitions are the most frequent genetic changes at P53 in gastric cancer 92
Adiponectin affects the mechanical responses in strips from the mouse gastric fundus 92
Study on aneuploidy and p53 mutations in astrocytomas 90
Aip-mutated acromegaly resistant to first-generation somatostatin analogs: Long-term control with pasireotide lar in two patients 90
Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: A novel model of invasive medullary thyroid carcinoma 88
The significance of p53 mutations in human cancers 84
Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer 84
Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment 83
Animal models of MEN1 79
Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma 78
Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development 77
Adipocyte-specific tribbles pseudokinase 1 regulates plasma adiponectin and plasma lipids in mice 72
Animal models of multiple endocrine neoplasia 71
Angpt2/Tie2 autostimulatory loop controls tumorigenesis 71
CDKN1B (p27) defects leading to pituitary tumors 70
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations 67
Obesity and cancer – extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases 66
The glucocorticoid receptor in brown adipocytes is dispensable for control of energy homeostasis 66
Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas 65
Editorial: Stem Cells in Endocrine Tumors 64
Animal and Cell Culture Models of PPGLs – Achievements and Limitations 63
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 61
An AMP-activated protein kinase–stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice 59
The norepinephrine transporter as a putative predictive biomarker for PI3K/mTOR inhibition in pheochromocytoma. 58
Tribbles Genes in Gastric Cancer: A Tumor-Suppressive Role for TRIB2 56
miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance 56
Multiple Endocrine Neoplasia Type 4 (MEN 4) 54
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures 54
Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics 53
Multiple Endocrine Neoplasia-Type 4 (MEN4) and Other MEN1-Like Syndromes 51
Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors 49
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging 49
Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region 44
Systematic mapping of mitochondrial calcium uniporter channel (MCUC)-mediated calcium signaling networks 42
Multiple Endocrine Neoplasia Type 4 42
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses 41
Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo 40
Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures 40
Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome 39
Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma 38
Morphology, Biochemistry, and Pathophysiology of MENX-Related Pheochromocytoma Recapitulate the Clinical Features 38
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study 37
Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models 35
Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormone 35
Primary Cell Culture Systems for Human Thyroid Studies 35
SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary 34
Inceptor correlates with markers of prostate cancer progression and modulates insulin/IGF1 signaling and cancer cell migration 34
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas 33
Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas 31
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model 30
Simultaneous magnetic resonance imaging of pH, perfusion and renal filtration using hyperpolarized 13C-labelled Z-OMPD 29
Obesity in MENX Rats Is Accompanied by High Circulating Levels of Ghrelin and Improved Insulin Sensitivity 26
Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome 24
Editorial: Obesity and metabolism in endocrine-related cancers 17
Mild chronic post-natal pain induces endocrine and metabolic alterations associated to enlargement in pituitary glands size in adult CD-1 male mice 15
Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant 11
Totale 4.355
Categoria #
all - tutte 21.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.841


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022156 0 0 10 6 1 7 2 24 8 4 15 79
2022/2023550 44 47 4 31 63 59 2 31 246 3 12 8
2023/2024259 19 50 12 21 20 30 41 31 1 14 11 9
2024/2025879 20 64 9 20 8 83 74 64 212 34 83 208
2025/20261.940 153 121 209 172 240 119 343 131 153 158 71 70
2026/2027139 50 89 0 0 0 0 0 0 0 0 0 0
Totale 4.355